×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ONCO – onconetix, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ONCO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
9/26
08:51 am
onco
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement [Yahoo! Finance]
High
Report
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement [Yahoo! Finance]
9/26
08:30 am
onco
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
Medium
Report
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
9/26
08:15 am
onco
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
Medium
Report
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
9/22
08:43 am
onco
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM [Yahoo! Finance]
High
Report
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM [Yahoo! Finance]
9/22
08:00 am
onco
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
Medium
Report
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/10
01:27 pm
onco
Form DEF 14A Onconetix, Inc. For: Dec 05
Low
Report
Form DEF 14A Onconetix, Inc. For: Dec 05
10/29
12:17 pm
onco
Form 8-K Onconetix, Inc. For: Oct 23
Low
Report
Form 8-K Onconetix, Inc. For: Oct 23
10/29
06:02 am
onco
Form PRE 14A Onconetix, Inc. For: Oct 28
Medium
Report
Form PRE 14A Onconetix, Inc. For: Oct 28
10/3
08:16 am
onco
Form 8-K Onconetix, Inc. For: Oct 01
Low
Report
Form 8-K Onconetix, Inc. For: Oct 01
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: